Skip to main content

Table 1 Dose Groups and Product Formulations

From: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

Dose Cohorts Number of patients in Cohort (Patient number) Peptides loaded/HLA class Peptide loading method and concentration DEX dose (expressed as numbers of MHC class II molecules)
A 3 (DU 5, 6, 8) MAGE-A3 (112–120)/class I
MAGE-A4 (230–239)/class I
MAGE-A10 (254–262)/class I
CMV pp65/class II
Tetanus toxoid/class II
Indirect (10 μg/mL)
Indirect (10 μg/mL)
Indirect (10 μg/mL)
Indirect (10 μg/mL)
Indirect (10 μg/mL)
0.13 × 10 14
B 5 (DU 24, 39, 44, 50, 63) MAGE-A3 (112–120)/class I
MAGE-A4 (230–239)/class I
MAGE-A10 (254–262)/class I
CMV pp65/class I
MAGE-A3 (247–258)/class II
Tetanus toxoid/class II
Direct (10 μg/mL)
Direct (10 μg/mL)
Direct (10 μg/mL)
Direct (10 μg/mL)
Indirect (10 μg/mL)
Indirect (10 μg/mL)
0.13 × 10 14
C 4 (DU 49, 73, 81, 83) MAGE-A3 (112–120)/class I
MAGE-A4 (230–239)/class I
MAGE-A10 (254–262)/class I
MAGE-A3 (247–258)/class II
Direct (100 μg/mL)
Direct (100 μg/mL)
Direct (100 μg/mL)
Indirect (10 μg/mL)
0.13 × 10 14
  1. The amino acid sequences of the peptides used for loading the dexosomes are: MAGE-A3(112–120) = KVAELVHFL; MAGE-A4(230–239) = GVYDGREHTV; MAGE-A10(254–262) = GLYDGMEHL; MAGE-A3(247–258) = TQHFVQENYLEY; CMV pp6 = NLVPMVATV; tetanus toxoid = QYIKANSKFIGITE
  2. Note: DU39, DU44, and DU83 were not treated.